Search results for "DISEASE PROGRESSION"

showing 10 items of 835 documents

The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome.

2008

Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in H…

medicine.medical_specialtyHeart diseaseDiseaseBioinformaticsstatin congestive heart failure metabolic sydromeHypolipemiaInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientPharmacologyHeart FailureMetabolic SyndromeClinical Trials as Topicbusiness.industryPublic healthmedicine.diseaseOxidative StressEndocrinologyHeart failureDisease ProgressionMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCurrent pharmaceutical design
researchProduct

Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multice…

2015

Lipoprotein apheresis (LA) can lower LDL-cholesterol and Lp(a) by 60%-70% and is the final escalating option in patients with hyperlipoproteinemias involving LDL or Lp(a) particles. Major therapeutic effect of LA is preventing cardiovascular events. In Germany since 2008 a reimbursement guideline has been implemented accepting to establish the indication for LA not only for familial or severe forms of hypercholesterolemia but also based on Lp(a)-hyperlipoproteinemia associated with a progressive course of cardiovascular disease, that persists despite effective treatment of other concomitant cardiovascular risk factors. The Pro(a)LiFe-study confirmed with a prospective multicenter design tha…

medicine.medical_specialtyHyperlipoproteinemiasTime FactorsDiseaseRisk AssessmentCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineMulticenter trialGermanyInternal MedicinemedicineHumansProspective StudiesFamily historyRetrospective Studiesbiologybusiness.industryTherapeutic effectGeneral MedicineGuidelineLipoprotein(a)medicine.diseaseSurgeryTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component RemovalDisease ProgressionCardiology and Cardiovascular MedicineRisk assessmentbusinessBiomarkersLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Calprotectin and spondyloarthritis

2017

medicine.medical_specialtyImmunologyGastroenterologyDisease activity03 medical and health sciences0302 clinical medicineInternal medicineAnimalsHumansImmunology and AllergyMedicineSpondylitis AnkylosingInflammation030203 arthritis & rheumatologyTumor Necrosis Factor-alphabusiness.industryPrognosisInfliximabGene Expression RegulationDisease Progression030211 gastroenterology & hepatologyImmunotherapyCalprotectinbusinessLeukocyte L1 Antigen ComplexBiomarkersExpert Review of Clinical Immunology
researchProduct

Clinical Benefits of Early Triptan Therapy for Migraine

2004

The introduction of the triptans brought advances in achieving complete and sustained pain resolution in migraine patients, compared with non-migraine-specific treatments. However, sustained pain-free rates for triptans recorded in many clinical trials are still relatively low. This may be due to study participants being treated late into the attack, when pain is already moderate or severe. Studies with almotriptan have shown that efficacy is enhanced when treatment is given early in a migraine attack while pain is still mild, compared with later administration when pain intensity is greater. Developments in our understanding of migraine pathophysiology provide a rationale for this phenome…

medicine.medical_specialtyIndolesCentral sensitizationMigraine DisordersTriptans03 medical and health sciences0302 clinical medicinePatient satisfactionIntervention (counseling)AlmotriptanSecondary PreventionmedicineHumans030212 general & internal medicinePractice Patterns Physicians'Intensive care medicineAnalgesicsClinical Trials as TopicEvidence-Based Medicinebusiness.industryDisease progressionGeneral Medicinemedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialTreatment OutcomeMigrainePatient SatisfactionAcute DiseaseDisease ProgressionPhysical therapyNeurology (clinical)businessAttitude to Health030217 neurology & neurosurgerymedicine.drugCephalalgia
researchProduct

Non-alcoholic fatty liver disease pathogenesis: The present and the future

2008

Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome. The prevalence of non-alcoholic fatty liver disease is around 20-30%, and with a rapid increase in the metabolic risk factors in the general population, non-alcoholic fatty liver disease has become the most common cause of liver disease worldwide. A fraction (20-30%) of non-alcoholic fatty liver disease patients develop a potentially progressive hepatic disorder, namely non-alcoholic steatohepatitis, leading to end-stage liver disease. The pathogenesis of non-alcoholic fatty liver disease is not entirely understood, and even if insulin resistance is a major pathogenetic key, many other factors are im…

medicine.medical_specialtyLipolysisPopulationPhysiologyApoptosisMitochondria LiverInsulin resistance Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis SteatosisDiseaseFatty Acids NonesterifiedPathogenesisLiver diseaseInsulin resistanceAdipokinesRisk FactorsInternal medicinemedicineAnimalsHumansGenetic Predisposition to Diseaseeducationeducation.field_of_studyHepatologybusiness.industryFatty liverGastroenterologymedicine.diseaseDietFatty LiverOxidative StressEndocrinologyAdipose TissueLiverDisease ProgressionHepatocytesCytokinesInsulin ResistanceSteatohepatitisMetabolic syndromebusinessDigestive and Liver Disease
researchProduct

Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.

2017

The indolent non-Hodgkin lymphomas (i-NHLs) are characterised by ‘indolent’ clinical behaviour with slow growth and prolonged natural history. The watchful waiting (WW) strategy is a frequently employed treatment option in these patients. This implies a strict monitoring by imaging examinations, including 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) and CT. A major concern is radiation exposure due to regularly monitoring by conventional imaging procedures. Several studies have demonstrated the reliability of whole-body magnetic resonance imaging (WB-MRI) for lymphoma staging. WB-MRI could be useful for active surveillance in i-NHLs providing the …

medicine.medical_specialtyLymphomamedicine.medical_treatmentWhole body imaging030218 nuclear medicine & medical imaging03 medical and health sciencesMagnetic resonance imaging0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicinemedia_common.cataloged_instanceHumansRadiology Nuclear Medicine and imagingWhole Body ImagingEuropean unionWatchful WaitingNeuroradiologymedia_commonmedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinReproducibility of ResultsMagnetic resonance imagingInterventional radiologyGeneral Medicinemedicine.diseaseLymphomaRadiation therapyDiffusion Magnetic Resonance Imaging030220 oncology & carcinogenesisDisease ProgressionIonising radiationRadiologybusinessWatchful waitingEuropean radiology
researchProduct

Lysine triggers apoptosis through a NADPH oxidase-dependent mechanism in human renal tubular cells

2012

Progressive chronic kidney disease (CKD) is common in lysinuric protein intolerance (LPI), a primary inherited aminoaciduria characterized by massive Lysine excretion in urine. However, by which mechanisms Lysine may cause kidney damage to tubule cells is still not understood. This study determined whether Lysine overloading of human proximal tubular cells (HK-2) in culture enhances apoptotic cell loss and its associated mechanisms. Overloading HK-2 with Lysine levels reproducing those observed in urine of patients affected by LPI (10 mM) increased apoptosis (+30%; p < 0.01 vs.C), as well as Bax and Apaf-1 expressions (+30-50% p < 0.05), while downregulated Bcl-2 (-40% p < 0.05). Apoptosis …

medicine.medical_specialtyLysineGene ExpressionApoptosisNADPH Oxidasecomplex mixturesAntioxidantsCell LineExcretionKidney Tubules ProximalInternal medicineGeneticsmedicineHumansRenal Insufficiency ChronicAmino Acid Metabolism Inborn ErrorsProtein SubunitGenetics (clinical)Membrane Potential MitochondrialKidneyNADPH oxidasebiologyLysineAmino Acid Metabolism Inborn ErrorNADPH OxidasesApoptosimedicine.diseaseCaspase InhibitorsLysinuric protein intoleranceIn vitroProtein SubunitsEndocrinologymedicine.anatomical_structureCell cultureApoptosisbiology.proteinCaspase InhibitorDisease ProgressionAntioxidantReactive Oxygen SpeciesReactive Oxygen SpecieHuman
researchProduct

Link of the mechanisms of action of glatiramer acetate to its long-term clinical data

2009

A consequence of the long-term nature of progression in multiple sclerosis is that treatment needs to be provided over the long term. Gathering evidence for long term clinical efficacy, safety and patient acceptance of immunomodulatory therapies is thus a critically important issue. However, pivotal trials, which generally last no more than two years, cannot address this issue. Glatiramer acetate is the only immunomodulatory treatment for which prospective data is available covering a treatment period of over a decade. In the long-term extension of the pivotal trial of glatiramer acetate, 108 patients have been followed for a mean treatment duration of 10.1 years. At the end of the treatmen…

medicine.medical_specialtyMultiple SclerosisTimeSecondary PreventionHumansMedicineClinical efficacyGlatiramer acetateIntensive care medicineClinical Trials as Topicbusiness.industryMultiple sclerosisGlatiramer AcetatePrognosismedicine.diseaseTreatment periodTerm (time)Clinical trialTreatment OutcomeNeurologyAmbulatoryDisease ProgressionPhysical therapyObservational studyNeurology (clinical)PeptidesbusinessRisk Reduction BehaviorImmunosuppressive Agentsmedicine.drugJournal of the Neurological Sciences
researchProduct

From transformation to chronification of migraine : pathophysiological and clinical aspects

2020

AbstractChronic migraine is a neurological disorder characterized by 15 or more headache days per month of which at least 8 days show typical migraine features. The process that describes the development from episodic migraine into chronic migraine is commonly referred to as migraine transformation or chronification. Ample studies have attempted to identify factors associated with migraine transformation from different perspectives. Understanding CM as a pathological brain state with trigeminovascular participation where biological changes occur, we have completed a comprehensive review on the clinical, epidemiological, genetic, molecular, structural, functional, physiological and preclinic…

medicine.medical_specialtyNeurologyMigraine Disorderslcsh:MedicineNeurophysiologyNeuroimagingNeuroimagingNeurological disorderReview ArticleBioinformaticsPathophysiologyEpigenesis GeneticTransformationChronic MigraineNeuroimagingEpidemiologyGeneticsMedicineHumansPathologicalChronic migrainebusiness.industrylcsh:RGeneral MedicineBiomarkermedicine.diseaseBiomarker (cell)Animal modelsAnesthesiology and Pain MedicineMigraineRisk factorsChronic DiseaseDisease ProgressionNeurology (clinical)business
researchProduct

In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy

2005

Background: Mouse models of colitis and cancer are indispensable for our understanding of the pathogenesis of these diseases. In the past, mice had to be sacrificed in order to analyse colitis activity and tumour development. We have developed a safe method for high resolution endoscopic monitoring of living mice. Methods: Mice developing colitis or colonic tumours were anaesthetised using avertine and repeatedly examined by endoscopy. A novel miniendoscope (1.9 mm outer diameter), denoted Coloview, was introduced via the anus and the colon was carefully insufflated with an air pump before analysis of the colonic mucosa. An extra working channel allowed the introduction of biopsy forceps or…

medicine.medical_specialtyPathologyColorectal cancerAzoxymethaneColonoscopyMice Inbred StrainsSeverity of Illness IndexGastroenterologyChromoendoscopyMiceIntestinal mucosaInternal medicineBiopsymedicineAnimalsIntestinal MucosaColitisGrading (tumors)Colonoscopesmedicine.diagnostic_testbusiness.industryDextran SulfateInflammatory Bowel DiseaseGastroenterologyCancerColonoscopyColitismedicine.diseaseDisease Models AnimalCell Transformation NeoplasticColonic NeoplasmsDisease ProgressionbusinessGut
researchProduct